Nyxoah SA (NYXH) Reports Q4 Loss, Lags Revenue Estimates

Stock Information for ImmunoPrecise Antibodies Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai(TM) Platform Powered by Patented HYFT® Technology
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference
IPA's LENSai(TM) Platform Delivers X-Ray-Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai(TM) with FDA's Shift to Non-Animal Testing Methods
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.